Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial.

needle-free alternative in the booming weight loss and diabetes market. Eli Lilly on Thursday said its daily obesity pill met the company's goals in the first of several late-stage trials ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

A trial was conducted comparing weight loss medications Zepbound and Wegovy ... one other weight-related health problem, but ...

This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...

Eli Lilly also said patients saw no plateau in their weight loss by the time the study ... There are seven late-stage studies on the pill, including five diabetes trials and two obesity studies.

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...